3-n-methylspiperone has been researched along with risperidone in 1 studies
Studies (3-n-methylspiperone) | Trials (3-n-methylspiperone) | Recent Studies (post-2010) (3-n-methylspiperone) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
---|---|---|---|---|---|
155 | 6 | 7 | 6,924 | 1,505 | 2,477 |
Protein | Taxonomy | 3-n-methylspiperone (IC50) | risperidone (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Eriksson, B; Farde, L; Halldin, C; Nyberg, S; Oxenstierna, G | 1 |
1 trial(s) available for 3-n-methylspiperone and risperidone
Article | Year |
---|---|
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Psychiatric Status Rating Scales; Raclopride; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Salicylamides; Schizophrenia; Schizophrenic Psychology; Spiperone; Tomography, Emission-Computed; Treatment Outcome | 1999 |